Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Sun Life Financial Inc. Common Stock (SLF) vs 10X Genomics Inc (TXG) Price & Performance

Sun Life Financial Inc. Common StockTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Sun Life Financial Inc. Common Stock vs 10X Genomics Inc — how do they compare? Sun Life Financial Inc. Common Stock trades at $77.62 (market cap $43.10B), while 10X Genomics Inc trades at $72.15 (market cap $9.35B). The key difference: Sun Life Financial Inc. Common Stock is far larger — about 4.6× 10X Genomics Inc's market cap, and Sun Life Financial Inc. Common Stock pays a 3.48% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sun Life Financial Inc. Common Stock for 0 Days and 10X Genomics Inc for 91 Days on average.

SLFTXG
Market Cap
$43.10B$9.35B
Volume
448,4204,039,449
Sector
FinancialsHealth
52-Week High
$84.07$97.74
52-Week Low
$57.60$11.83
Typical Hold Time
0 Days91 Days
Enterprise Value
$44.83B$8.88B
Dividend Yield
3.48%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Sun Life Financial Inc. Common Stock

Sun Life Financial (SLF) trades at $77.87, up 0.69% on the day, reflecting steady momentum. The stock shows consistent earnings beats in recent quarters, with Q3 2026 results pending. Financial health is solid, with a P/E of 18.82 and robust cash flow projections for 2026. Recent strategic moves include expanding disability benefits and forming a reinsurance partnership, signaling growth initiatives.

The outlook for SLF is cautiously optimistic, supported by earnings strength and strategic expansions. Key risks include competitive pressures and macroeconomic volatility. Analyst sentiment is mixed, with a majority hold rating, suggesting potential stability but limited near-term upside. Investors should weigh solid fundamentals against sector headwinds.

10X Genomics Inc

TXG trades at $73.10, down 2.78% on the day, with a bearish technical signal and neutral oscillators. The company reported revenue of $642.82M in 2025 but a net loss of $43.54M, though recent quarters show earnings beats. Analyst consensus is mixed with a $83.30 price target. Positive news includes Atera shipments and a patent victory, but profitability remains a challenge.

The outlook hinges on Atera's commercial success driving future revenue growth and margin improvement. Risks include persistent losses, competitive pressures, and execution delays. Upside potential exists if new platforms gain traction, but investors should weigh high valuation multiples against ongoing unprofitability.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

SLF
100% Buy0% Sell
Avg holding period · 0 Days
TXG
17% Buy83% Sell
Avg holding period · 91 Days

Top news

Latest headlines on both assets

About Sun Life Financial Inc. Common Stock

Sun Life Financial Inc. is a Canada-based financial services company providing insurance, wealth and asset management, and health solutions for individuals and institutions. Its products span life, health, and disability insurance along with mutual funds and pension asset management, through operations in Canada, US, the United Kingdom, Ireland, and across Asia.

Read more on SLF →

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG →